Last edition
News about "Accord BioPharma"
US FDA Approves Accord BioPharma's ENNUMO Pegfilgrastim Biosimilar
The US Food and Drug Administration (FDA) has approved Accord BioPharma’s ENNUMO (pegfilgrastim-pccg), expanding its US biosimilar portfolio and strengthening access to G-CSF therapies for cancer patients.
Accord BioPharma | 10/07/2026 | By News Bureau
Accord BioPharma has received US FDA approval for Immgolis and Immgolis Intri, the first golimumab biosimilars approved in the United States for rheumatoid arthritis and ulcerative colitis treatment.
Accord BioPharma | 19/05/2026 | By News Bureau | 133
Accord BioPharma Launches IMULDOSA Prefilled Syringes at Lowest WAC Price
Accord BioPharma has announced the commercial launch of IMULDOSA (ustekinumab-srlf), a biosimilar to STELARA (ustekinumab).
Accord BioPharma | 19/08/2025 | By Dineshwori | 448
Intas Pharmaceuticals Acquires UDENYCA from Coherus BioSciences
Intas Pharmaceuticals, along with its global subsidiaries operating under the Accord brand, has acquired UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences, strengthening its global biosimilar portfolio and strengthening its position in the pegfilgrastim market.
Accord BioPharma | 07/08/2025 | By Mrinmoy Dey | 298
Accord BioPharma Signs Exclusive US Licensing Deal with Bio-Thera for BAT2506
BAT2506 is a proposed golimumab biosimilar developed by Bio-Thera. Golimumab, a human monoclonal antibody, inhibits the biological activity of tumor necrosis factor alpha (TNF-alpha).
Accord BioPharma | 11/02/2025 | By Aishwarya | 840
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy